Latest News

Could one surgery replace years of GA injections? Phase 2 ArMaDa data suggest gene therapy OCU410 slows lesion growth.

Kareem Moussa, MD, discusses how four local corticosteroid injections compare on effectiveness and IOP, and what that means for choosing among them.

4DMT's 4D-150 gene therapy enters phase 3 4SIGHT trial in DME; 2-year SPECTRA data show +10.8-letter BCVA gain in 9 patients.

Serena Salvatore, MD, discusses the retinal laser training gap, persistent laser myths, simulation and practical advice for safer laser at EURETINA 2026.

Ester Carreño, MD, PhD, explains how to tell retinitis pigmentosa from uveitis and why genetic confirmation now matters more.

Women’s systemic and ocular health associated with pregnancy is a focus at EURETINA 2026 in Vienna.

Three EURETINA 2026 e-posters examine OCT/OCTA biomarkers and real-world switching to faricimab or aflibercept 8 mg in nAMD.

Three studies use OCT and OCTA to track AMD treatment response, flag diabetic retinopathy before oedema and confirm ocular toxoplasmosis.

Japan's filing covers IRDs broadly, supported by RESTORE and open-label Stargardt data.

An industry symposium on intravitreal 4D-150 and a course on subretinal delivery lead gene therapy content at EURETINA 2026, alongside IRD courses and trial readouts.

Tarcocimab, tabirafusp-ted were noninferior to aflibercept in DAYBREAK wet AMD trial; 54% on tarcocimab reached 24-week dosing.

Alessandro Arrigo, MD, describes an early-stage method that uses blue light autofluorescence imaging to grade cataracts objectively. He explains why a reproducible score could help with surgeon selection, IOL power calculation, and retinal image quantification.

Study found anti-VEGF therapy was linked to kidney function decline in patients with diabetic retinopathy or retinal vein occlusion.